New cocktail of drugs takes on multiple myeloma
NCT ID NCT04108195
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests combinations of the drug daratumumab with two newer bispecific antibodies (talquetamab and teclistamab), with or without pomalidomide, in 290 people with multiple myeloma. The main goal is to find safe doses and understand side effects. Participants must have had at least three prior treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
daratumumab, talquetamab, teclistamab, pomalidomide
What this could lead to
If successful, this could point toward a new combination treatment for multiple myeloma that is more effective than current options.
What could go wrong
This is an early Phase 1b study focused on safety and dosing, not yet on effectiveness. The combinations may cause serious side effects or fail to work better than existing therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2, Canada
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California, 92618, United States
-
Clinica Univ. de Navarra
Pamplona, 31008, Spain
-
Germans Trias I Pujol
Barcelona, 08916, Spain
-
Hosp Clinic de Barcelona
Barcelona, 08036, Spain
-
Hosp Clinico Univ de Salamanca
Salamanca, 37007, Spain
-
Hosp Univ Fund Jimenez Diaz
Madrid, 28040, Spain
-
Inst. Cat. Doncologia-H Duran I Reynals
Barcelona, 08908, Spain
-
LUMC
Leiden, 2333ZA, Netherlands
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
Medical College Of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Mount Sinai Medical Center
New York, New York, 10029, United States
-
The Blavatnik Family Chelsea Medical Center at Mount Sinai
New York, New York, 10011, United States
-
Universitaetsklinikum Hamburg Eppendorf
Hamburg, 20246, Germany
-
Universitaetsklinikum Heidelberg
Heidelberg, 69120, Germany
-
Universitatsklinikum Freiburg
Freiburg im Breisgau, 79106, Germany
-
Universitatsklinikum Wurzburg
Würzburg, 97080, Germany
-
University Health Network UHN Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
University of California San Francisco
San Francisco, California, 94143, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
VU Medisch Centrum
Amsterdam, 1081 HV, Netherlands
-
Vanderbilt Ingram Cancer Center
Nashville, Tennessee, 37232, United States
-
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, 27157, United States